-
Mashup Score: 2BODHI • โพธิ์ (@bodhi.indy) • Instagram photo - 7 month(s) ago
43 likes, 2 comments – bodhi.indy on October 11, 2023: “𝙅𝙤𝙞𝙣 𝘽𝙊𝘿𝙃𝙄 𝙞𝙣 𝙎𝙪𝙥𝙥𝙤𝙧𝙩𝙞𝙣𝙜 𝘾𝙝�…”
Source: www.instagram.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0BODHI • โพธิ์ (@bodhi.indy) • Instagram photo - 7 month(s) ago
43 likes, 2 comments – bodhi.indy on October 11, 2023: “𝙅𝙤𝙞𝙣 𝘽𝙊𝘿𝙃𝙄 𝙞𝙣 𝙎𝙪𝙥𝙥𝙤𝙧𝙩𝙞𝙣𝙜 𝘾𝙝�…”
Source: www.instagram.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Join us tomorrow evening at Bodhi Restaurant in #Indianapolis to raise funds for our #sickecell and #thalassemia program @RileyChildrens! @RileyKids https://t.co/jxcOSV8uPr
-
-
Mashup Score: 0Past, present, and future management strategies for non-transfusion dependent β-thalassemia - 8 month(s) ago
Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon, delves into the management strategies for non-transfusion dependent beta-thalassemia (NTDT). Prof. Taher emphasizes the importance of targeting ineffective erythropoiesis and iron chelation therapy in this group of patients to decrease morbidity and increase the quality of life (QoL). Prof. Taher also mentions the development of novel therapies including luspatercept, mitapivat, and gene therapies. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EHA2023 | @AliTaherMD discusses management strategies for non-transfusion dependent β-thalassemia and further comments on the development of novel therapies in this space: 🎥 https://t.co/mRWFDMckfn #RareDiseases #Thalassemia
-
-
Mashup Score: 2
– First CRISPR gene-editing filings to be accepted for review by FDA – – FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT) – – PDUFA target action date of December 8, 2023 , for SCD and March 30, 2024 , for TDT –…
Source: Vertex Pharmaceuticals NewsroomCategories: Hem/Oncs, Latest HeadlinesTweet-
🚨 #GeneTherapy news: @US_FDA accepts @VertexPharma Exa-cel BLA for #SickleCell and #Thalassemia; big shout out to @hfrangoul and @SarahCannonDocs Transplant & Cellular Therapy Program @TriStarHealth - they are among largest enrollers on CLIMB trials https://t.co/34MWXVyfKM
-
-
Mashup Score: 0
Investigators evaluated the link between gout and thalassemia using data from Taiwan’s Longitudinal Health Insurance Database 2000 (LHID 2000).
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Investigators evaluated the link between #gout and #thalassemia using data from Taiwan's Longitudinal Health Insurance Database 2000 (LHID 2000). Learn more: https://t.co/NaQAomcKCV
-
-
Mashup Score: 0Transfusion Management of Beta (β) Thalassemia - 1 year(s) ago
A Thalassemia Resource for Healthcare Providers
Categories: Latest Headlines, PediatricsTweet-
Healthcare providers: Learn about #bloodtransfusions in #thalassemia and what to consider when recommending transfusions for patients living with this #blooddisorder: https://t.co/ViFyGSRrEF https://t.co/TeDSR0CMjn
-
-
Mashup Score: 0Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia - 1 year(s) ago
Key Point. The use of Hu and thalidomide combination in β-thalassemia resulted in fewer transfusions and increased Hb levels.
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet-
Evaluation of the combination therapy of hydroxyurea and thalidomide in β-#thalassemia https://t.co/st1ujNScyd https://t.co/J18cZSiIOP
-
-
Mashup Score: 0Target Ferritin Level Achieved With Long-Term Deferiprone in Thalassemia With Iron Overload | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination November 21, 2022 Deferiprone (DFP) was an effective iron chelator for patients with thalassemia, with more than half achieving a target serum ferritin (SF) level with long-term use, according to a study of…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#Deferiprone is found to be an effective iron chelator for patients with #thalassemia, with more than half of study patients achieving a target serum ferritin level with long-term use https://t.co/W0BOOfPzqY
-
-
Mashup Score: 0HCT Represents Cure for Thalassemia Major, But Long-Term Risks Remain | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination November 21, 2022 Hematopoietic cell transplantation (HCT) has the potential to cure the majority of patients with thalassemia major, according to Stella Santarone, MD, of the Bone Marrow Transplant Center at…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#Hematopoietic cell transplantation (#HCT) has the potential to cure many patients with #thalassemia #major, but the risk of early and late mortality in these individuals still remains https://t.co/21C9EgAoCD
-
-
Mashup Score: 0Registration - 2 year(s) ago
Meet our guest speaker Antonis Kattamis, Professor of Paediatric Hematology and Oncology at the University of Athens, Greece. Kattamis has presented at several congresses including ASH, EHA, and Thalassemia International Federation, and has published more than 100 articles in the field of haemoglobinopathies and iron metabolism. The topics covered in this session will include: • Optimal…
Source: register.gotowebinar.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This educational webinar will focus on optimal strategies for carrier screening and prenatal diagnosis of α- and β- #thalassemia as well as the cultural/ethnical characteristics to be taken in consideration. Register now: https://t.co/0AIddHHcCA #thalassemiapatients #webinar https://t.co/qVqAXQYDVZ
-
Join us tomorrow evening at Bodhi Restaurant in #Indianapolis to raise funds for our #sicklecell and #thalassemia program @RileyChildrens! @RileyKids @IU_Health @IUNewsroom https://t.co/jxcOSV8uPr